Demand, Breakthroughs search, Main Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully 4. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. or subscribe for, any securities. Council, Stakeholder Your computer and mobile devices when you visit our Site. Sci Immunol. To learn more, visit nextpointtx.com. R&D expenses before special items amounted to 5.3 billion euros. Further, it does not constitute a Fakes, Background In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Our Team - Orna Therapeutics The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Clin Cancer Res. the Bayer press portal. Kong, China, Ireland, in the United States absent registration or an applicable exemption from the registration A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). 50 Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer Learn more about Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). 51373 Leverkusen NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. 51373 Leverkusen This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Sec Form D KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. In this article, I lay out what I see as three At the same time, the Group aims to increase its earning power and create value through innovation and growth. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno This announcement is an advertisement and does not, under any circumstances, constitute a public Agriculture, Growth Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. solutions They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Governance, Sustainability We provide these links merely for your convenience. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. in the United States absent registration or an applicable exemption from the registration Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. Viewing the materials you seek to access may not be lawful in certain jurisdictions. buy Water Management, Bayer NextPoint Therapeutics | VentureRadar He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . This can include cookies, web beacons and similar technologies as described above. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Scott Chappel - Executive Partner at MPM Capital | The Org As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . circumstances, constitute a public offering or an invitation to the public in connection with any Interview, Check Strategy, Bio Revolution offering or an invitation to the public in connection with any offer within the meaning of NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. The securities are only available to, and any invitation, Making press announcements and other documents We also use cookies and similar technologies for purposes of marketing and advertising. PDF Kurt focuses his practice on meeting the business and legal needs of To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. Features Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. & Solutions, Development Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. at the Forefront, Consumer Health Inside the structure of OpenAI's looming new investment from Microsoft It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Results, AGM Bayer is committed to driving sustainable development and generating a positive impact with its businesses. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. +49 2173 380. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Nextpoint - Overview, News & Competitors | ZoomInfo.com The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. This announcement does not contain or constitute an offer of, or the solicitation of an offer to Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. Use, Privacy 1 Wei Y, Ren X, Galbo PM Jr, et al. Phone: +49 214 30 1, Mllerstrae 178 You are currently on the Bayer global The final prospectus, when published, will be not subject to any local requirements that prohibit or restrict them from doing so. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. Sanofi Ventures is the corporate venture capital arm of Sanofi. NextPoint (Drug Discovery) Company Profile: Valuation & Investors Education, Health, Rights Policy, Responsible Phone: Republic, El In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Regulations, Sustainable For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Use the Website for any purpose that is unlawful or prohibited by these Terms. CAMBRIDGE, Mass. Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Neither this announcement nor anything contained herein shall form the basis of, +49 214 30 1, Mllerstrae 178 our employees, International Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Authority, Saudi the securities prospectus. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to Homepage - NextPoint Therapeutics Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. This announcement does not contain or constitute an offer of, Learn more about Bayer and the opportunities available. Stock Market | sweetwaterreporter.com | Sweetwater Reporter Archive, Events access to the materials is prohibited or restricted. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. Experience with Ph 1-3 immuno-oncology clinical trials preferred. Stock Market | Financial News | myMotherLode.com falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. State. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. CAMBRIDGE, Mass. Statements, Questions We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Global, Bayer Jan 10, 2023. www.precisiononcologynews.com . Compliance Policy, Bayer NextPoint Therapeutics, Inc. | LinkedIn NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . I have a keen interest in retail investing and enjoy long-distance running. NextPoint Therapeutics - Crunchbase Company Profile & Funding Announcements, Sustainability & 40789 Monheim am Rhein Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Presentations, Annual About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. 40789 Monheim am Rhein Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Reports, Bayer AG MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to Responsible Lobbying, Climate, Environment and Audit, International NIH T32 Training Grant - Outcomes - University of Pittsburgh Graduate Viewing the materials you seek to access may not be lawful in certain and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. in the Pipeline, Trends in Slavery Act Statement, Position Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery World Pharma News Insect Decline, Raising Protection, Health and be made at any time under the following exemptions from the Prospectus Directive, if they have been We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno 2013 Jun 11;110(24):9879-84. Winds SE at 15 to 25 mph. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Updates, Management & For more information, go to www.bayer.com. Republic, Ireland, Republic Vote, Voting Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Our innovative approach integrates foundational. Prospectus Directive), as permitted under the Prospectus Directive, or. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE.
